雅各臣科研制药二零二三年中期报告

225 26 27 4 28 5 38811232313-18 Conyers Trust Company (Cayman) LimitedCricket SquareHutchins DrivePO Box 2681Grand Cayman KY1-1111Cayman Islands 1617 jacobsonpharma@sprg.com.hk 2633 www.jacobsonpharma.com Cricket SquareHutchins DrivePO Box 2681Grand Cayman KY1-1111Cayman Islands 10 SAP • • • • 2019 22.9%714.917.813.1%154.0 EBITDA218.117.8%871.0 IILosartan TabletsHydralazinePrazosinTabletsEplerenone Tablets Arsenic Trioxide Oral Solution 1.5Brimonidine 1.5mg Eye Drops5FinasterideTablet 5mgMetronidazole Oral SuspensionDexamethasone Oral Suspension 12.65%6.34% Letrozole Tablets18 18163115517 27.24% 19 e-Jacob Pharma2U e-Jacob Pharma2UUATe-Jacob Pharma2Ue-Jacob Pharma2U 492,259,2442,000509 1,5881,567215.4182.0 133.022.9% 96%124.522.1% 7.385.4%3.037.0% 85.726.1%44%32%24% 71.665.0% 11.39.4%2.82.9% 2.71.7%166.022.113.1 24.817.6% 27.9142.2% 22.1 30.520.7%177.928.223.9 52.642.0% 68.4133.423.122.1 17.7860.6 59.4 99.5%98.9% 116.0130.0 695,540,00098,438,000 *(a)4.1(b) 73.9 100%15.6%17.8%152.2 872.0 C.2.1 13.1813.21 13.1813.21 1,400,000,00036872,000,000 (i)(a)(b)51%51%(ii) (a)(b)12(c)12(d)(b) 241024 2.548.42.89 1617 13.51B(1) 878 XVXV78352347 (1)14,350,000Queenshill308,404,000Queenshill308,404,000UBS Trustees (B.V.I.) LimitedThe Kingshill TrustUBS NomineesLimitedKingshill Development Group IncTrust CoTrust CoKingshillKingshill850,684,000The Kingshill TrustThe QueenshillTrustThe Kingshill TrustThe Queenshill TrustKingshill850,684,000The Queenshill TrustTheQueenshill TrustThe Queenshill Trust8,200,000The Queenshill TrustThe Queenshill Trust8,200,000 XVXV78352347 XV23336 (1)QueenshillQueenshill308,404,000 (2)UBS Trustees (B.V.I.) LimitedThe Kingshill TrustUBS Nominees LimitedTrust CoTrust CoKingshillKingshill850,684,000The Kingshill TrustThe Queenshill TrustUBS Trustees (B.V.I.) LimitedTrust CoKingshill850,684,000 (4)The Queenshill TrustThe Queenshill TrustThe QueenshillTrust8,200,000The Queenshill TrustTheQueenshill Trust8,200,000 (5)2.06200,000,000200,000,000200,000,000 (6)Longjin Investments LimitedLongjin75%Longjin157,050,000 336 138,000,0007.13% 301 121% (i)(ii)(iii) 37,000,00037,000,000 3%120.5%120.1% 21,650,0004,750,000 (1) (2)21 (3) 0.92 25463434 2410 34 1 2 34 3 34 241024 3 (A) •17•8•12•12 17 17417 3 (A) 8 12 12 12 (B) 2022 1993(b) 3 4 (A) 15 (B) EBITDAEBITDA 19 4 (B) (i) 4 (B) (iii) (iv) 10%335,003,000293,677,000 6 7 16.5%16.5% 8 (A) 8 (B) 9 10 (A) 10,464,00024,859,000 20192019208,000 162019 (B) 12,654,0008,863,00077,000264,00031,000183,000 11 15 (B) (i) 10 3% 120.5%0.1% 22,756,00019,486,000 4,750,00010,000,000 15 (B) (ii) 136,000,0002.06 11,000,0002.13 (iii) 10 5% 121.0%0.1% 3,036,0003,814,00038,000 16 (A) (i) 13 106,743,00067,067,000 16 (A) (ii) 1%3,173,0002,604,00015,287,00012,989,000 1%1,034,0001,034,0001,162,0001,162,000 (B) 17 18 19 9(B) 19 19 (C) 28,217,000(i)(ii) 20 21 22 19